Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

BOULDER, Colo.–(BUSINESS WIRE)– #AI–Initially developed for atopic dermatitis, Enveda’s lead asset ENV-294 is now showing promise in treating asthma.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks